By Fineline Cube 
China-based Luye Pharma Group (HKG: 2186) announced that it has received marketing approval from Japan’s Ministry of Health, Labour and Welfare for its rivastigmine twice weekly transdermal patch. The product, branded as Rivaluen LA Patch 25.92mg/51.84mg in Japan, is now approved for suppressing the progression of dementia symptoms in mild to moderate Alzheimer’s disease. This marks the first approval of its kind in Japan.
Partnership and Licensing
Luye Pharma entered into a partnership with Japan-based Towa Pharmaceutical Co., Ltd., a central nervous system (CNS) specialist, in December 2020. The agreement granted Towa an exclusive license for the development and commercialization of the rivastigmine twice weekly transdermal patch in Japan.
Global Expansion
The product has already been approved in multiple countries across Europe and China. Luye Pharma is further expanding its reach by registering the product in selected countries in Southeast Asia and Latin America through local partnerships.-Fineline Info & Tech